Significant correlation between uric acid levels and flow-mediated dilatation in patients with masked hypertension

Clinical and Experimental Hypertension

Volumn 36, Issue 5, 2014, Pages 315-320

  Sincer, Isa ^a   Kurtoglu, E ^b   Caliskan, M ^c   Akkaya, E ^a   Vuruskan, E ^a   Kucukosmanoglu M ^a   Çoşkun, F Yilmaz ^a   Inci, M F ^d   Zorlu, A ^e  

^a Gaziantep 25 Aralik Hospital   (Turkey)

^b Department of Cardiology Elazig Education and Research Hospital ^*  (Turkey)

^c Medeniyet University Medical Faculty   (Turkey)

^d KSU Medical School   (Turkey)

^e CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Endothelial function; Flow mediated dilatation; Masked hypertension; Uric acid

Indexed keywords

URIC ACID;

ADULT; AORTA; ARTERY DIAMETER; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FLOW MEDIATED DILATATION; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; MORBIDITY; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; VASODILATATION; AGED; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS; DILATATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADULT; AGED; BLOOD PRESSURE; DIABETES MELLITUS; DILATATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MASKED HYPERTENSION; MIDDLE AGED; RISK FACTORS; URIC ACID;

EID: 84903785082     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2013.827694     Document Type: Article

References (45)

1. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90. (Pubitemid 36706063)
2. Carnethon MR, Fortmann SP, Palaniappan L, et al. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003;158: 1058-67. (Pubitemid 37475089)
3. Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003;18:523-30. (Pubitemid 36899556)
4. Suliman ME, Johnson RJ, Garcia-Lopez E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006;48: 761-71. (Pubitemid 44740052)
5. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study. Hypertension 2000;36:1072-8.
6. Sundström J, Sullivan L, D'Agostino R, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension 2005;45: 28-33. (Pubitemid 40066409)
7. Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005;96:1576-8. (Pubitemid 41690182)
8. Bunim JJ, McEwan C. Tophus of mitral valve in gout. Arch Pathol 1960;29:700-4.
9. Trant EF, Knight AA. Specific vascular changes in gout. JAMA 1954;156:591-602.
10. Boogaerts MA, Hammerschmidt DE, Roelant C, et al. Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulo-cyte mediated, endothelial injury. Thromb Haemost 1983;50: 576-80. (Pubitemid 13048239)
11. Sakr SA, Abbas TM, Amer MZ, et al. Microvascular angina. The possible role of inflammation, uric acid, and endothelial dysfunction. Int Heart J 2009;50:407-19.
12. Kawano Y. Uric acid and blood pressure. Circ J 2011;75:2755-6.
13. Zoccali C, Maio R, Mallamaci F, et al. Uric acid and endothelial dysfunctio in essential hypertension. J Am Soc Nephrol 2006;17: 1466-71. (Pubitemid 43673429)
14. Erhardt JG, Estes JE, Pfeiffer CM, et al. Combined measurement of ferritin, soluble transferin receptor, retinol binding protein, and C-reactive protein by an inexpensive, sensitive, and simple sandwich enzyme-linked immunosorbent assay technique. J Nutr 2004;134: 3127-32. (Pubitemid 39470095)
15. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291: 1342-9. (Pubitemid 38541649)
16. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-18. (Pubitemid 8066109)
17. Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 2011;33:298-304.
18. Gur M, Yilmaz R, Demirbaǧ R, et al. Relationship between elastic properties of the aorta and uric acid levels in newly diagnosed hypertensive patients. Arch Turk Soc Cardiol 2006;34:223-9. (Pubitemid 351309245)
19. Kanbay M, Turkmen K, Ecder T, Covic A. Ambulatory blood pressure monitoring: from old concepts to novel insights. Int Urol Nephrol 2012;44:173-82.
20. Cuspidi C, Parati G. Masked hypertension: an independent predictor of organ damage. J Hypertens 2007;25:275-9. (Pubitemid 46071922)
21. Mann S, Altman DG, Raftery EB, Bannister R. Circadian variation of blood pressure in autonomic failure. Circulation 1983;68: 477-83. (Pubitemid 13005496)
22. Sherwood A, Routledge FS, Wohlgemuth WK, et al. Blood pressure dipping: ethnicity, sleep quality, and sympathetic nervous system activity. Am J Hypertens 2011;24:982-8.
23. Kaya MG, Yarlioglues M, Gunebakmaz O, et al. Platelet activation and inflammatory response in patients with non-dipper hypertension. Atherosclerosis 2010;209:278-82.
24. Mazzali M, Kanbay M, Segal MS, et al. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010;12:108-17.
25. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005;45:18-20. (Pubitemid 40066407)
26. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90. (Pubitemid 36706063)
27. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-16. (Pubitemid 44901524)
28. Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995;6: 1313-17.
29. Eslami P, Corry DB, Nyby MD, Tuck ML. Inhibition of oxidative stress and improvement of nitric oxide production by ACE inhibitors and AT1 receptor blockers in uric acid stimulated vascular smooth muscle cells. Am J Hypertens 2004;17:S154-5.
30. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991;266:8604-8. (Pubitemid 21906552)
31. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739-42. (Pubitemid 40577708)
32. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-93. (Pubitemid 36706079)
33. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-81. (Pubitemid 128373654)
34. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005;45:18-20. (Pubitemid 40066407)
35. Iwashima Y, Horio T, Kamide K, et al. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006;47:195-202. (Pubitemid 43189763)
36. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-46. (Pubitemid 40279622)
37. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739-42. (Pubitemid 40577708)
38. Zoccali C, Maio R, Mallamaci F, et al. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006;17: 1466-71. (Pubitemid 43673429)
39. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-93. (Pubitemid 36706079)
40. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE 2011;6: e19901.
41. Coutinho Tde A, Turner ST, Peyser PA, et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007;20: 83-9. (Pubitemid 46014067)
42. Johnson RJ, Rodriguez-Iturbe B, Kang DH, et al. A unifying pathway for essential hypertension. Am J Hypertens 2005;18: 431-40. (Pubitemid 40409928)
43. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19: 1814-22. (Pubitemid 28556651)
44. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 2008;371:2219-21.
45. White WB. Systolic versus diastolic blood pressure versus pulse pressure. Curr Cardiol Rep 2002;4:463-7.